Entera Bio Ltd.
Entera Bio Ltd. is a clinical-stage biotechnology company developing oral tablet versions of peptide and protein replacement therapies. Its lead work centers on the N-Tab platform and first-in-class oral programs in osteoporosis and metabolic disease, including EB613, EB612, and oral GLP-1/GLP-2-related candidates.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaDevelopment of oral tablet formulations designed to replace injectable peptide and protein therapies.
EB613, EB612 and oral OXM programs targeting osteoporosis and metabolic disease.
N-Tab™ delivery technology used to enable oral administration of biologics.
Contract research and material transfer services performed for third parties.
Asiakkaat
Entera does not yet sell approved products to commercial end customers; its current economic counterparties are research collaborators, grant providers, and development partners. The company’s future customers would be patients and prescribers in osteoporosis and metabolic disease if its oral peptide candidates are approved and commercialized.
Third parties that pay for material transfer and research services while Entera performs contract R&D work.
Potential users of EB613 if approved, seeking an oral alternative to injectable PTH therapy.
Potential users of oral GLP-1/Glucagon or GLP-2 therapies if the programs reach commercialization.
Partners that may license, co-develop, or fund oral peptide programs to access the platform.
Strategia
Entera is focused on advancing first-in-class oral versions of peptide therapies that are normally delivered by injection, with the goal of changing treatment convenience and adherence. Near term, the company is prioritizing EB613 phase 3 preparation, next-generation EB613 work, and completion of oral OXM studies with OPKO while preserving cash and securing additional funding.
EB613 is the most advanced program and could validate the platform in a large osteoporosis market.
The collaboration can expand the pipeline into metabolic disease while sharing development burden.
Platform validation across multiple peptides can improve partnering leverage and long-term optionality.
Clinical development requires capital and the company has stated additional funding will be needed.
Maantiede
Entera’s operations are centered in Jerusalem, Israel, where all employees are based and core R&D work is performed. The company also relies on advisors and contract manufacturing and clinical activity in the United States, the United Kingdom, Europe, and Asia, so its development footprint is international even though the operating base is Israeli.
Riskit
Entera is a pre-revenue clinical-stage company, so execution risk is concentrated in clinical outcomes, regulatory approvals, and financing. Its Israeli operating base also creates geopolitical and operational exposure, while future commercialization depends on proving that oral peptide delivery can work reliably and be accepted by regulators and partners.
- Geopolitical risk in IsraelVaikutus: KorkeaTodennäköisyys: Kohtalainen
Employees and operations are based in Israel, so conflict could disrupt work, supply chains, or fundraising.
Kohdistuu: Jerusalem operations and personnel
- Financing riskVaikutus: KorkeaTodennäköisyys: Matala
The company expects to need additional capital before commercialization and may not raise it on favorable terms.
Kohdistuu: Operating runway and trial funding
- Clinical development failureVaikutus: Korkea
EB613, EB612 and oral OXM are still in development and may not demonstrate safety or efficacy.
Kohdistuu: Lead pipeline programs
- Regulatory riskVaikutus: Korkea
The company needs FDA and other regulatory alignment before advancing into later-stage trials and approval.
Kohdistuu: EB613 phase 3 planning
- Partner and collaboration riskVaikutus: Keskitaso
Development timelines and economics depend partly on third-party collaboration agreements.
Kohdistuu: OPKO collaboration and research services
Kirjanpito
Harkinnanvaraiset erätRevenue is recognized using labor hours and elapsed time, so timing depends on project progress rather than product sales.
Vaikutus: Quarterly revenue can be small and uneven
IIA-related grants can create future repayment or royalty exposure if conditions are triggered.
Vaikutus: Potential contingent liability and cash outflow
R&D, lab, manufacturing, and trial costs are expensed as incurred, driving operating losses before commercialization.
Vaikutus: Material effect on reported earnings and burn rate
Equity awards are a meaningful compensation tool for a small biotech workforce.
Vaikutus: Affects R&D and G&A expense
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
ENDRA Life Sciences Inc.
NDRA · Electromedical & Electrotherapeutic Apparatus
Atara Biotherapeutics, Inc.
ATRA · Biological Products, (No Diagnostic Substances)
Atara Biotherapeutics is a U.S.-based biotechnology company focused on T-cell immunotherapy built around its allogeneic Epstein-Barr virus (EBV) T-cell platform.
Olema Pharmaceuticals, Inc.
OLMA · Pharmaceutical Preparations
Olema Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies for…
Oramed Pharmaceuticals Inc
ORMP · Pharmaceutical Preparations
Entrada Therapeutics, Inc.
TRDA · Pharmaceutical Preparations
Entrada Therapeutics is a clinical-stage biopharmaceutical company developing genetic medicines designed to reach intracellular targets that have historically been difficult to access.
Tyra Biosciences, Inc.
TYRA · Pharmaceutical Preparations
Päivitetty: 24.9.2026